Seer Inc is a life sciences company, develops and commercializes products to decode the biology of the proteome. The company offers Proteograph Product Suite, an integrated solution that includes proprietary engineered nanoparticles, consumables, automation instrumentation, and data analysis software to perform proteomic analysis to provide a solution that can be incorporated by nearly any lab for research use only. It markets and sells its products for research use only, which cover academic institutions, life sciences, and research laboratories, as well as biopharmaceutical and biotechnology companies for non-diagnostic and non-clinical purposes. The company operates in China, Australia, Eastern Europe, Israel, Japan and South Africa.
Last trade$1.44
Day change-$0.04 (-2.70%)
Day range$1.42 – $1.55
Volume125,357
Market cap$83M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$82.61M
Price / earnings
—
Price / book
0.39×
Price / sales
5.87×
EV / sales
3.79×
EV / EBITDA
-0.88×
Profitability
Earnings per share
-$1.14
Return on assets
-26.25%
Return on equity
-29.81%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0×
Current ratio
16.89×
Quick ratio
16.24×
Cash ratio
2.95×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$46.35M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for SEER, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$3.98M
$3.1M
$2.79M
$4.2M
$4.12M
$4.05M
$4.21M
$4M
Cost of revenue
$2.1M
$1.6M
$1.81M
$2.02M
$2.01M
$1.94M
$2.14M
$1.98M
Gross profit
$1.88M
$1.51M
$982K
$2.18M
$2.11M
$2.11M
$2.06M
$2.03M
Selling, general and administrative
$10.11M
$10.14M
$9.43M
$9.83M
$10.66M
$10.66M
$11.44M
$12.89M
Research and development
$6.44M
$8.21M
$8.81M
$9.74M
$10.8M
$11.99M
$11.35M
$12.62M
Total operating expenses
$16.55M
$18.35M
$18.24M
$19.57M
$21.46M
$22.64M
$22.79M
$25.51M
Operating income
-$14.67M
-$16.84M
-$17.26M
-$17.39M
-$19.35M
-$20.53M
-$20.73M
-$23.49M
Interest expense
$0
$0
$0
$0
$0
$0
$0
$0
Income before taxes
-$13.73M
-$16.89M
-$16.83M
-$15.97M
-$18.21M
-$19.38M
-$19.85M
-$21.64M
Income taxes
$5K
$9K
$10K
$28K
$24K
$48K
$101K
$98K
Net income
-$13.74M
-$16.9M
-$16.84M
-$15.99M
-$18.23M
-$19.42M
-$19.95M
-$21.74M
Net income attributable to common shareholders
-$13.74M
-$16.9M
-$16.84M
-$15.99M
-$18.23M
-$19.42M
-$19.95M
-$21.74M
EBITDA
-$13.27M
-$15.35M
-$15.73M
-$15.88M
-$17.89M
-$18.99M
-$19.13M
-$21.88M
Basic earnings per share
-$0.25
-$0.31
-$0.30
-$0.29
-$0.32
-$0.33
-$0.34
-$0.37
Diluted earnings per share
-$0.25
-$0.31
-$0.30
-$0.29
-$0.32
-$0.33
-$0.34
-$0.37
Recent news
Company coverage with links to the original publishers.
Seer, Inc. announced the re-election of all seven director nominees to its Board of Directors based on preliminary voting results from its 2026 Annual Meeting of Stockholders held on July 28, 2026. The company expressed confidence in its board's qualifications and commitment to advancing shareholder interests, while outlining its strategic focus on expanding platform utilization, securing biobank studies, advancing innovation, and scaling commercialization with cost discipline.
Seer, Inc. filed an investor presentation ahead of its July 28, 2026 Annual Meeting, highlighting progress against strategic goals including 62% CAGR in installed base growth, 36% decrease in annual cash burn since 2022, and a robust innovation pipeline. The company's Board unanimously recommends voting for its seven director nominees and opposes activist investors Bradley Radoff and Michael Torok's campaign to force an early sale, arguing their proposals lack actionable value creation ideas and their nominees lack relevant proteomics expertise.
Seer, Inc. announced it has received an unsolicited acquisition proposal from Bradley L. Radoff and Michael Torok (Radoff-JEC Group) to acquire all outstanding Class A common stock for $2.25 per share in cash plus a contingent value right. The Radoff-JEC Group has also nominated three director candidates for the 2026 Annual Meeting. Seer's Board will carefully review the proposal and present its formal recommendation in the definitive proxy statement.
Seer, Inc. announced its participation in the 2026 U.S. Human Proteome Organization (US HUPO) Annual Conference with over a dozen scientific presentations showcasing how its Proteograph Product Suite enables deep, scalable proteomics research across cardiovascular disease, neurodegeneration, aging biology, and oncology. The company will feature a breakfast symposium on nanoparticle-enabled plasma proteomics and multiple plenary and poster presentations demonstrating the technology's ability to detect thousands of proteins from small-volume samples.
Seer presented multiple scientific studies at HUPO 2025, demonstrating how their Proteograph platform enables deep proteomics research across cardiovascular, aging, and cancer biology, showcasing the technology's potential for population-scale discovery and clinical translation.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.